← Leaderboards
Rajendra G Mehta
University Of Illinois At Chicago
$5,791,028
Attributed
$5,791,028
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $465.9K · FY2005–14$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$5,791,028 · 5
By mechanism
R01$4,944,488 · 3
P01$633,978 · 1
N01$212,562 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Alan Diamond$5,594,746
- Richard V Benya$5,336,057
- Steven M Swanson$4,071,879
- John M Pezzuto$2,202,476
- Lisa Tussing-Humphreys$6,306,920
Others in their field
Top investigators on “Carcinogenesis Inhibitor”
- John A Tainer · Scripps Research Institute$14,596,069
- Allan Balmain · University Of California San Francisco$13,081,271
- Max Costa · New York University School Of Medicine$10,709,689
- Zigang Dong · University Of Minnesota Twin Cities$10,323,424
- Harold Fisher Dvorak · Beth Israel Deaconess Medical Center$9,216,408
- Erle S Robertson · University Of Michigan At Ann Arbor$7,902,036
Research focus
Carcinogenesis InhibitorChemopreventionVitamin DBreast NeoplasmsCell LineWomanResearch StudyIn VivoMediatingLaboratoriesSignal TransductionResponseAdenocarcinomaMethylnitrosoureaCancer PreventionFemaleMammary GlandVitamin AnalogNutrition Related TagChemical CarcinogenesisLaboratory RatNutrition Aspect Of CancerColon Cancer Cell LineAnalog
Grant awards (19)
Deguelin in therapy of triple negative breast cancer$453,776
R01 · FY2014 · CA · contact PI
Deguelin in therapy of triple negative breast cancer$438,848
R01 · FY2013 · CA · contact PI
Deguelin in therapy of triple negative breast cancer$465,889
R01 · FY2012 · CA · contact PI
Deguelin in therapy of triple negative breast cancer$464,897
R01 · FY2011 · CA · contact PI
Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention$374,940
R01 · FY2010 · CA · contact PI
Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention$374,940
R01 · FY2009 · CA · contact PI
Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention$374,940
R01 · FY2008 · CA · contact PI
Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention$374,940
R01 · FY2007 · CA · contact PI
Vitamin D5 in Prevention of Mammary Carcinogenesis$301,298
R01 · FY2006 · CA · contact PI
Vitamin D5 in Prevention of Mammary Carcinogenesis$301,380
R01 · FY2005 · CA
Vitamin D5 in Prevention of Mammary Carcinogenesis$297,843
R01 · FY2004 · CA
Vitamin D5 in Prevention of Mammary Carcinogenesis$201,746
R01 · FY2003 · CA
CORE--MOUSE MAMMARY ORGAN CULTURE$228,401
P01 · FY2002 · CA
VITAMIN D5 IN PREVENTION OF MAMMARY CARCINOGENSIS$178,157
R01 · FY2002 · CA
CORE--MOUSE MAMMARY ORGAN CULTURE$228,401
P01 · FY2001 · CA
VITAMIN D5 IN PREVENTION OF MAMMARY CARCINOGENSIS$172,965
R01 · FY2001 · CA
EVAUATION OF CHEMOPREVENTIVE AGENTS BY IN VITRO SCREENIN$212,562
N01 · FY2000 · CN
CORE--MOUSE MAMMARY ORGAN CULTURE$177,176
P01 · FY2000 · CA
VITAMIN D5 IN PREVENTION OF MAMMARY CARCINOGENSIS$167,929
R01 · FY2000 · CA